Osteoporosis is associated with anti-topoisomerase I positivity and glucocorticoids use in patients with systemic sclerosis.

IF 4.7 2区医学 Q1 RHEUMATOLOGY

Rheumatology Pub Date : 2025-03-01 DOI:10.1093/rheumatology/keae142

Charles Midol, Edgar Wiebe, Elise Siegert, Dörte Huscher, Hélène Béhal, David Launay, Eric Hachulla, Eric L Matteson, Frank Buttgereit, Vincent Sobanski

{"title":"Osteoporosis is associated with anti-topoisomerase I positivity and glucocorticoids use in patients with systemic sclerosis.","authors":"Charles Midol, Edgar Wiebe, Elise Siegert, Dörte Huscher, Hélène Béhal, David Launay, Eric Hachulla, Eric L Matteson, Frank Buttgereit, Vincent Sobanski","doi":"10.1093/rheumatology/keae142","DOIUrl":null,"url":null,"abstract":"Objectives: Patients with systemic sclerosis (SSc) are at increased risk for osteoporosis (OP) and associated fragility fractures. This study aimed to identify underlying risk factors for these conditions in patients with SSc.Methods: This cross-sectional study was based on a large prospective cohort of patients with SSc using retrospectively collected bone health data. OP was defined as the presence of a T-score below -2.5 at the femoral neck or lumbar spine, a previous major osteoporotic fracture, or the prescription of anti-osteoporotic therapy.Results: A total of 485 patients fulfilling the ACR/EULAR 2013 diagnostic criteria for SSc, followed in the Lille University Hospital, were included in the study. The prevalence of OP was 23%; fragility fractures occurred in 18% of patients. OP was associated with higher age, diffuse cutaneous subset, interstitial lung disease (ILD), anti-topoisomerase I positivity, treatment with glucocorticoids (GC) and DMARDs in univariable analysis. Multivariable analysis indicated that higher age (OR 1.06 [95%CI 1.04-1.08]), anti-topoisomerase I antibody positivity (OR 2.22 [1.18-4.16]) and treatment with GC (OR 4.48 [2.42-8.26]) were significantly and independently associated with OP.Conclusion: Our study shows that OP risk in patients with SSc is determined by age, disease-related factors such as diffuse cutaneous subset, ILD and anti-topoisomerase I antibody positivity, but also treatment with GC independently of other factors.","PeriodicalId":21255,"journal":{"name":"Rheumatology","volume":" ","pages":"1270-1276"},"PeriodicalIF":4.7000,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Rheumatology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1093/rheumatology/keae142","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"RHEUMATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Objectives: Patients with systemic sclerosis (SSc) are at increased risk for osteoporosis (OP) and associated fragility fractures. This study aimed to identify underlying risk factors for these conditions in patients with SSc.

Methods: This cross-sectional study was based on a large prospective cohort of patients with SSc using retrospectively collected bone health data. OP was defined as the presence of a T-score below -2.5 at the femoral neck or lumbar spine, a previous major osteoporotic fracture, or the prescription of anti-osteoporotic therapy.

Results: A total of 485 patients fulfilling the ACR/EULAR 2013 diagnostic criteria for SSc, followed in the Lille University Hospital, were included in the study. The prevalence of OP was 23%; fragility fractures occurred in 18% of patients. OP was associated with higher age, diffuse cutaneous subset, interstitial lung disease (ILD), anti-topoisomerase I positivity, treatment with glucocorticoids (GC) and DMARDs in univariable analysis. Multivariable analysis indicated that higher age (OR 1.06 [95%CI 1.04-1.08]), anti-topoisomerase I antibody positivity (OR 2.22 [1.18-4.16]) and treatment with GC (OR 4.48 [2.42-8.26]) were significantly and independently associated with OP.

Conclusion: Our study shows that OP risk in patients with SSc is determined by age, disease-related factors such as diffuse cutaneous subset, ILD and anti-topoisomerase I antibody positivity, but also treatment with GC independently of other factors.

查看原文本刊更多论文

系统性硬化症患者骨质疏松症与抗拓扑异构酶 I 阳性和使用糖皮质激素有关。

目的：系统性硬化症（SSc）患者发生骨质疏松症（OP）和相关脆性骨折的风险增加。本研究旨在确定系统性硬化症患者出现这些情况的潜在风险因素：这项横断面研究基于一个大型前瞻性 SSc 患者队列，使用回顾性收集的骨健康数据。OP的定义是股骨颈或腰椎的T值低于-2.5、曾发生过重大骨质疏松性骨折或接受过抗骨质疏松治疗：研究共纳入了 485 名符合 ACR/EULAR 2013 SSc 诊断标准、在里尔大学医院接受随访的患者。OP的发病率为23%；18%的患者发生了脆性骨折。在单变量分析中，OP与较高的年龄、弥漫性皮肤亚组、间质性肺病（ILD）、抗拓扑异构酶I阳性、糖皮质激素（GC）和DMARDs治疗有关。多变量分析表明，较高的年龄（OR 1.06 [95%CI 1.04-1.08]）、抗拓扑异构酶 I 抗体阳性（OR 2.22 [1.18-4.16]）和糖皮质激素治疗（OR 4.48 [2.42-8.26]）与 OP 有显著的独立相关性：我们的研究表明，SSc 患者的 OP 风险由年龄、疾病相关因素（如弥漫性皮肤亚组、ILD 和抗拓扑异构酶 I 抗体阳性）以及 GC 治疗决定，与其他因素无关。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Rheumatology 医学-风湿病学

CiteScore

9.40

自引率

7.30%

发文量

1091

审稿时长

2 months

期刊介绍： Rheumatology strives to support research and discovery by publishing the highest quality original scientific papers with a focus on basic, clinical and translational research. The journal’s subject areas cover a wide range of paediatric and adult rheumatological conditions from an international perspective. It is an official journal of the British Society for Rheumatology, published by Oxford University Press. Rheumatology publishes original articles, reviews, editorials, guidelines, concise reports, meta-analyses, original case reports, clinical vignettes, letters and matters arising from published material. The journal takes pride in serving the global rheumatology community, with a focus on high societal impact in the form of podcasts, videos and extended social media presence, and utilizing metrics such as Altmetric. Keep up to date by following the journal on Twitter @RheumJnl.